Stemtech Corp (OTCMKTS: STEK) is seeing one massive drop after another in recent trading as this major league promotion falls apart. At the top of the promotion at $11.50 per share STEK market cap crossed the $1 billion mark, an astronomically high number considering the Company has minimal assets, $33 million in liabilities and averages a little over $1 million in revenues per quarter. STEK recent action is very similar to GESI which we called out too fairly early on. We stated on STEK in early August: STEK has been rocketing up the charts in recent trading initially rocketing up in July from $5 to $9, dropping back down to $4 and rocketing up northbound again recently surpassing $9.90 per share. STEK is a major league promotion from some heavy hitters that could easily go much higher but when the bottom falls out, it could drop fast.”
We think STEK could continue to move lower and will eventually trade below $0.25 per share similar to where GESI is. However, as the drop has been particularly precipitous, with STEK dropping from over $4 to under $1 in just the last week, there could be some significant bounces on the way down. According to management they have no idea what’s going on stating in a recent press release: “they were notified by OTC Markets of a foreign stock promotion which we were unaware of, and provided Stemtech Corporation with a copy of an article from a UK web site called “World Finance”, which emphatically predicted share price appreciation in the Stem Cell arena in general, and our Company in particular.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Stemtech Corp (OTCMKTS: STEK) is a global network marketing company that develops science-based products that it believes supports wellness by helping the body maintain healthy stem cell physiology, also known as stem cell enhancers. Known as the Stem Cell Nutrition Company®, the Company is a pioneer in stem cell science, and believes it can demonstrate that adult stem cells function as the natural renewal system of the body. The Company believes its products enhance and support the work of the body’s stem cells by releasing more stem cells, helping to circulate them in the blood and migrate them into tissues, where they can perform their daily function of renewal for optimal health. The Company’s mission is to enhance wellness and prosperity around the world. These products are marketed internationally by the Companies subsidiaries and through independent distributors. The Company markets its products under the following brands: RCM System, stemrelease3™, Stemflo® MigraStem™, DermaStem®, DermaStem Lift, OraStem® (Oral Health Care), and D-Fuze™.
Stemtech has pioneered and patented a whole new category of dietary supplements. Stemtech’s advanced Stem Cell Nutrition formulations are one-of-a-kind natural products designed to help support the three most important aspects of stem cell physiology: 1) Releasing more stem cells; 2) their circulation in the blood; and 3) Migration into tissues, where they can perform their daily function of renewal and rejuvenation for optimal health. We actually harness the incredible power of adult stem cells. How does this work? Adult stem cells are released from your bone marrow into the bloodstream, they then Circulate in the bloodstream and flow to the tissues most in need. As they arrive, the adult stem cells migrate into the tissues, reproduce and become new, healthy cells of those tissues. This process takes place every single day, even without tissue damage, as part of the natural renewal system of the body. It is important to understand that Stemtech’s products do not contain stem cells. They are composed of natural botanicals and other ingredients that have been clinically documented to support the performance of your own adult stem cells.
The Company is now reengaging over 200,000 former distributors since a recent cash infusion. STEK has engaged experienced marketing and social media professionals to initiate new marketing strategies which are expected to bring increased activity. Moreover, it is now better positioned to absorb significant new clientele as the company has directed significant cash towards our inventory, and we now have enough inventory on hand to fulfill over $3 million dollars’ worth of new orders, an inventory level we have not had since going into bankruptcy in 2017. Management conservatively believes that given the cash on hand and working expenditures as describe above, it can reinvigorate sales to be more consistent with the company’s previous revenue historically, as it was recognized 4 times in the Inc 5000 Magazine’s list of fastest growing companies.
$STEK is a scam…
— Anthony Bocanegra (@AnthonyB__54) September 8, 2022
To Find out the inside Scoop on STEK Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
In August STEK signed an LOI to acquire Life Factor Research, a scientific research and development company. Stemtech Corporation President and Chief Operating Officer, John W. Meyer, said “the acquisition of Life Factor Research (LFR) provides Stemtech with an important in-house Research and Development Division which will provide all stem cell nutrition, other stem-ceuticals™, skin care and more cutting-edge ‘revolutionary’ stem cell products. This acquisition is made to position Stemtech at the very scientific forefront of advanced stem cell technology, developing more health-benefit products as well as expanding our Independent Business Partner base, enabling them to have a higher income earning opportunity.”
Life Factor Research CEO, Charles “Cliff” Layton says “having spent the last 35-plus years building the relationships which have enabled LFR to participate in creating the proprietary formulas, using compounds and proven technologies, we are extremely optimistic as to what an alliance with Stemtech will afford us. Our desire to create and control category leading nutraceuticals has been and will continue to be our focus. When combined with the technologies and distribution present in the current Stemtech model, we see levels of success obtainable by working together that could very well redefine much of what the market holds as standards and platitudes today.”
On September 6 STEK announced Professor Dr. Bankole Johnson joins the Stemtech Corporation Life Sciences Advisory Board (LSAB). Stemtech Corporation President and Chief Operating Officer, John W. Meyer, said “Professor Dr. Bankole Johnson joining Stemtech’s Life Sciences Advisory Board is a great addition to our Team. The world- recognized Dr. Johnson will provide guidance, insight and direction as we continue to focus on health betterment through science. Dr. Johnson joins Dr. Enrique Martinez, M.D. (U.S.) and Dr. Lizette Leos, M.D. (Mexico) on the LSAB.”
Charles S. Arnold, Stemtech Corporation Chairman and CEO stated that “with the addition of Professor Dr. Bankole Johnson, Stemtech continues to make forward strides toward our strategic goal of providing leading-edge and advanced products for health and wellness. Dr. Johnson’s participation will enable Stemtech to more aggressively achieve those heights.”
Professor Dr. Bankole Johnson gained national attention for his appearance in the Home Box Office (HBO) 2007 documentary Addiction, which won the Governor’s Award (a special Emmy Award) from the Academy of Television Arts and Sciences. This being the highest award presented by the Academy. He also appeared on the esteemed 2009 CNN special, anchored by Chief Medical Correspondent Dr. Sanjay Gupta, called Addiction: Life on the Edge. Furthermore, Professor Dr. Bankole Johnson is a regular medical correspondent for major network channels in the USA, especially during the COVID-19 pandemic.
Presently, Dr. Johnson is the Founder, Executive Chairman, and CEO of Casa Privée, based in Miami, and the Founder and Chief Medical Officer of Adial Pharmaceuticals Inc., a NASDAQ listed company. Professor Dr. Johnson also functions as a Professor of Biomedical Sciences at Larkin University in Miami.
— Shortable Stocks (@shortablestocks) September 12, 2022
For More on STEK Subscribe Right Now!
Currently trading at a $94 million market valuation, STEK OS is 44,945,673 and the float is 6,483,034 shares. STEK is an SEC filer and fully reporting OTCQB. The Company has just over $500,000 in the treasury and $5.1 million in assets vs. $30 million in liabilities. STEK is starting to book small revenues reporting $1,156,308 in sales for the 3 months ended March 31, 2022 up from $1,075,761 for the same period last year. STEK is a major league promotiont that is now predictably falling apart. We think STEK could continue to move lower and will eventually trade below $0.25 per share similar to where GESI is. However, as the drop has been particularly precipitous, with STEK dropping from over $4 to under $1 in just the last week, there could be some significant bounces on the way down. We will be updating on STEK when more details emerge so make sure you are subscribed to Microcapdaily.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in STEK either long or short and we have not been compensated for this article.